logo

For the Inventor, By the Inventor

Fairfield, OH, United States of America

Russell James Sheldon

This inventor holds 21 USPTO granted patents, plus 1 CIPO patent, primarily in Muscle Mass Regulation. Top assignee: The Procter Gamble Company. Active years: 1998-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Russell James Sheldon. Retrieved from https://idiyas.com/inventor/russell-james-sheldon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 81.0

 

Average Co-Inventor Count = 3.4

ph-index = 11

Forward Citations = 289(Granted Patents)


Company Filing History:

goldMedal21 out of 17,173 
 
The Procter Gamble Company
 patents

Years Active: 1998-2009

Loading Chart...
Loading Chart...
Areas of Expertise:
Corticotropin Receptors
Dopamine Receptors
Vasoactive Intestinal Peptide
Melanocortin Ligands
Alpha-2 Adrenoceptor
Guanidinyl Compounds
Imidazolinyl Compounds
Heterocycle Compounds
Adrenoceptor Agonists
Compound Identification
21 patents (USPTO):Explore Patents
1. 7572768 - Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors (2009-08-11),
2. 7067113 - Methods for identifying compounds for regulating muscle mass or function using dopamine receptors (2006-06-27),
3. 7063954 - Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors (2006-06-20),
4. 6951916 - Melanocortin receptor ligands (2005-10-04),
5. 6750194 - Methods of identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors (2004-06-15),
6. 6670140 - Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors (2003-12-30),
7. 6613874 - Melanocortin receptor ligands (2003-09-02),
8. 6436978 - Guanidinylamino heterocycle compounds useful as &agr;-2 adrenoceptor agonists (2002-08-20),
9. 6423724 - 7-(2-imidazolinylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists (2002-07-23),
10. 6395764 - 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agnonists (2002-05-28),
11. 6391878 - Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists (2002-05-21),
12. 6306877 - Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists (2001-10-23),
13. 6225331 - Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists (2001-05-01),
14. 6172095 - Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists (2001-01-09),
15. 6162818 - 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor (2000-12-19),

Title: Innovator Spotlight: Russell James Sheldon

Introduction: Russell James Sheldon, a prolific inventor based in Fairfield, OH (US), has made significant contributions to the field of muscle function regulation through his groundbreaking research and patented innovations.

Latest Patents: Among his impressive portfolio of 21 patents, Russell James Sheldon's latest inventions focus on methods for identifying compounds that regulate muscle mass or function using corticotropin-releasing factor receptors and dopamine receptors. These patents showcase his dedication to advancing treatments for skeletal muscle-related conditions such as atrophy and muscular dystrophies.

Career Highlights: Currently employed at The Procter & Gamble Company, Russell James Sheldon continues to drive innovation in the healthcare and pharmaceutical industry. His expertise in biochemistry and pharmacology has led to the development of novel screening methods and pharmaceutical compositions aimed at enhancing skeletal muscle mass and function.

Collaborations: Russell James Sheldon has collaborated closely with notable coworkers such as Raymond Todd Henry and William Lee Seibel. Together, they have worked on cutting-edge research projects that have resulted in the successful identification of compounds targeting corticotropin-releasing factor receptors and dopamine receptors for therapeutic interventions.

Conclusion: In conclusion, Russell James Sheldon stands as a pioneering figure in the realm of muscle function regulation, with a track record of patented inventions that have the potential to revolutionize treatments for muscular conditions. His dedication to innovation and collaboration underscores his commitment to advancing the field of biochemistry and pharmaceutical sciences.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…